NCT02799095 : A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy,Treatment | Skin,Urinary systemKidney,Melanoma (Skin),Renal cell carcinoma

Trial Overview Read MoreRead more

This phase I/II trial is trying to understand how safe and tolerable a new immunotherapy is for the treatment of advanced cancer.
 

This trial is treating patients with advanced solid cancers, in particular patients with melanoma or renal cell carcinoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1

Commercial Sponsor

Alkermes, Inc.

Summary

Eligible patients will assigned to one of two groups. In these groups, patients will either receive the investigational immunotherapy (ALKS 4230) alone via intravenous infusion over a 30 minute period, daily, for five consecutive days; OR in combination with intravenous pembrolizumab on the first day of each cycle.

Recruiting Hospitals Read MoreRead more

Border Medical Oncology
Albury
Ms Nyree Sarakis
Nsarkis@bordermedonc.com.au
02 6064 1493

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next